Results Show Promising Efficacy in MCL With Next-Generation BTK Inhibitor LOXO-305
Cancer Network,
Investigators on the BRUIN trial reported impressive response rates across multiple B-cell malignancies with the use of the…
LOXO-305, A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated Mantle Cell Lymphoma, Waldenström’s Macroglobulinemia, and Other Non-Hodgkin Lymphomas: Results from…
Overview of attention for article published in Blood, November 2020
Altmetric Badge
About this Attention Score
-
Above-average Attention Score compared to outputs of the same age (64th percentile)
-
Above-average Attention Score compared to outputs of the same age and source (57th percentile)
Readers on
- mendeley
- 14 Mendeley